![Anne-Marie Lund Winther](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenance du réseau au premier degré de Anne-Marie Lund Winther
Entité | Type d'entité | Industrie | |
---|---|---|---|
Pcovery ApS
![]() Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.
10
| Holding Company | Pharmaceuticals: Major | 10 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Anne-Marie Lund Winther via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
IMMUNOMEDICS, INC. | Biotechnology | Director/Board Member | |
Boehringer Ingelheim GmbH
![]() Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
FENNEC PHARMACEUTICALS INC. | Pharmaceuticals: Major | Chairman | |
H. LUNDBECK A/S | Pharmaceuticals: Major | Sales & Marketing | |
MOLMED S.P.A. | Pharmaceuticals: Major | Director/Board Member | |
NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
![]() Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal | |
Imperial College London | College/University | Doctorate Degree | |
University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
Johann Wolfgang Goethe-Universität Frankfurt am Main | College/University | Doctorate Degree | |
Takeda A/S
![]() Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Corporate Officer/Principal | |
University of Milan | College/University | Corporate Officer/Principal | |
Omnes Capital SAS /Venture/
![]() Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Investment Managers | Private Equity Investor | |
Novo Ventures 1 A/S
![]() Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal | |
OxThera AB
![]() OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member | |
Marion Merrell Dow (Europe) AG | Corporate Officer/Principal | ||
Chelsea College | College/University | Undergraduate Degree | |
PROMETHERA Biosciences SA
![]() PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Kurma Biofund FCPR
![]() Kurma Biofund FCPR Investment ManagersFinance Kurma Biofund seeks investment opportunities in life science and biotechnology companies located in Europe. The investments are done in cooperation with medical institutes and universities such as Institut Pasteur and Institut Curie. Its investment size ranges between €0.10 and €6 million. | Investment Managers | Corporate Officer/Principal | |
Aurigene Discovery Technologies Ltd.
![]() Aurigene Discovery Technologies Ltd. BiotechnologyHealth Technology Aurigene Discovery Technologies Ltd. operates as biotechnology company. It offers research services such as integrated research and stand-alone research. The company is headquartered in Bangalore, India. | Biotechnology | Director/Board Member | |
Boehringer Ingelheim (Venture Capital)
![]() Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Contera Pharma ApS
![]() Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chief Executive Officer | |
Sound Biotechnology, Inc. | Founder | ||
Konticon Consulting, Inc. | Chief Executive Officer | ||
Minervax ApS
![]() Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Director/Board Member | |
Conrig Pharma ApS
![]() Conrig Pharma ApS Pharmaceuticals: MajorHealth Technology Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Founder | |
Sirius Healthcare Partners GmbH
![]() Sirius Healthcare Partners GmbH Investment ManagersFinance Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland. | Investment Managers | Founder | |
Adenium AB | Chairman | ||
Minoryx Therapeutics SL
![]() Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Chairman | |
Prev AbR LLC
![]() Prev AbR LLC BiotechnologyHealth Technology Prev AbR LLC develops biologic and beta-lactamase compounds. The private company is based in Bethesda, MD. The company was founded by Khalid Islam. | Biotechnology | Founder | |
Inthera Bioscience AG
![]() Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member Chairman | |
Cardior Pharmaceuticals GmbH
![]() Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member | |
PROCESSA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
GTM-Halle SASU
![]() GTM-Halle SASU HomebuildingConsumer Durables Part of VINCI SA, GTM-Halle SASU is a French company founded in 2007 that specializes in construction and technical resources. The company is based in Laxou, France. GTM-Halle has worked on various projects including the construction of Custines College, Bénamenil College, and Decomble de Chaumont Lycée. The company has also been involved in health and medico-social projects such as the construction of Residence Domitys Calliope, EHPAD Korian, and hospital centers. The technical and operational resources department of GTM-Halle integrates all the necessary means to deploy on construction sites from the study phase. | Homebuilding | Chairman | |
GT Gain Therapeutics SA
![]() GT Gain Therapeutics SA Pharmaceuticals: MajorHealth Technology GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland. | Pharmaceuticals: Major | Chairman | |
AgomAb Therapeutics NV
![]() AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Elion Oncology, Inc.
![]() Elion Oncology, Inc. Pharmaceuticals: MajorHealth Technology Elion Oncology, Inc. engages in the provision of pharmaceutical services. The company was founded in 2016 and is headquartered in Bethesda, MD. | Pharmaceuticals: Major | Director/Board Member | |
Embark Biotech ApS
![]() Embark Biotech ApS Miscellaneous Commercial ServicesCommercial Services Novo Nordisk Research Center Gladsaxe ApS is based in Bagsværd, Denmark. The Danish company is a spin-out from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen. The company discovered a novel target that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity. The development of the target was initiated through a collaboration with Novo Nordisk and further matured with support from the Innobooster program at the Innovation Fund Denmark and the Bioinnovation Institute (BII) during a residency in the Venture House program. Part of Novo Nordisk A/S, Novo Nordisk Research Center Gladsaxe ApS is a biotech company that was founded in 2017. The CEO of the company is Casper Tind Hansen. Novo Nordisk Research Center Gladsaxe was acquired by Novo Nordisk A/S from Embark Laboratories ApS on August 28, 2023 for $68.06 million. | Miscellaneous Commercial Services | Chief Executive Officer | |
Draupnir Bio ApS
![]() Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Pharmaceuticals: Major | Chairman | |
GAIN THERAPEUTICS, INC. | Biotechnology | Founder | |
BioAim LLC | Founder | ||
Life Sciences Management GmbH | Chief Executive Officer | ||
Hoechst Marion Roussel Group
![]() Hoechst Marion Roussel Group BiotechnologyHealth Technology Part of Sanofi, Hoechst Marion Roussel Group designs molecule inhibitors. The company is based in Frankfurt, Germany. | Biotechnology | Corporate Officer/Principal | |
Aloop Therapeutics ApS
![]() Aloop Therapeutics ApS Pharmaceuticals: MajorHealth Technology Aloop Therapeutics ApS manufactures pharmaceutical preparations. The company is based in Copenhagen, Denmark. The CEOs are Søren Sylvester Skjærbæk, Thomas Kirkegaard Jensen. The Danish company was founded in 2022. | Pharmaceuticals: Major | Director/Board Member | |
IO BIOTECH, INC. | Biotechnology | Director/Board Member |
Statistiques
Internationale
Danemark | 16 |
Etats-Unis | 10 |
Allemagne | 6 |
Suisse | 6 |
France | 4 |
Sectorielle
Health Technology | 26 |
Finance | 9 |
Consumer Services | 6 |
Commercial Services | 3 |
Transportation | 2 |
Opérationnelle
Director/Board Member | 35 |
Corporate Officer/Principal | 20 |
Chairman | 19 |
Founder | 13 |
Chief Executive Officer | 10 |
Relations les plus connectées
- Bourse
- Insiders
- Anne-Marie Lund Winther
- Connexions Sociétés